Psychiatr. praxi 2019; 20(2): 77-81 | DOI: 10.36290/psy.2019.017

Monitoring of adverse events and safety of antidepressants

prof. MUDr. Eva Češková, CSc.1,2,3,4, PharmDr. Kateřina Horská2,5,6
1 CEITEC‑MU, Brno
2 Psychiatrická klinika FN Brno
3 KNP LF LF Univerzity Ostrava

Primum non nocere is one of the fundamental principles in medicine. All psychopharmaceuticals, in addition to their therapeutic effects, also have adverse events. Adverse events of individual drugs are known and included in the SPC (Summary of Product Characteristics), and it is the psychiatrist’s responsibility to inform patients about adverse events. Apart from subjective discomfort, adverse events are a major reason for treatment discontinuation. Therefore, the choice of antidepressant medication should be based particularly on individual vulnerability to adverse events. Furthermore, safety and tolerability should be monitored continuously; structured questionnaires and symptom scales should be preferred for their assessment and measurement. When an adverse reaction occurs, we can either reduce the dose, change or cease the treatment, or continue the treatment with adjunctive medication. Besides common adverse events, some serious and unexpected adverse events can occur which must be reported to the State Institute for Drug Control, the Department of Pharmacovigilance. However, the number of reports is low. The reasons may include lack of physicians’ motivation, poor availability of report outcomes, ignorance, and frequent off-label indications. Both international and national guidelines for the treatment of depressive disorder recommend off-label drugs on the basis of more recent scientific findings. Guideline updates are undoubtedly more flexible than SPC updates. Knowledge of risk factors and tolerability of adverse events in individual patients is necessary for individualized approach to the treatment.

Keywords: pharmacovigilance, antidepressants, adverse events, guidelines, individualized treatment

Published: June 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E, Horská K. Monitoring of adverse events and safety of antidepressants. Psychiatr. praxi. 2019;20(2):77-81. doi: 10.36290/psy.2019.017.
Download citation

References

  1. Dodd S, Mitchell PB, Bauer M. et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World J Biol Psychiatry 2018; 19: 330-348. Go to original source... Go to PubMed...
  2. Suchopár J, Prokeš M. Spotřeba antidepresiv v České republice ve srovnání s ostatními vyspělými zeměmi Remedia 2016; 26: 560-566.
  3. Kantor E, Rehm C, Haas J, Chan A, Gioannucci E. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015; 314: 1818-1831. Go to original source... Go to PubMed...
  4. Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: results of the German multicentre drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 Suppl 1: S39-45. Go to original source... Go to PubMed...
  5. Schmid C, Grohmann R, Engel RR, Rüther E, Kropp S. Cardiac adverse effects associated with psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: S65-69. Go to original source... Go to PubMed...
  6. Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, Rüther E, Cordes J. Cutaneous adverse reactions to psychotropic drugs: Data from a multicentre surveillance program. J Clin Psychiatry 2009; 70: 1258-1265. Go to original source... Go to PubMed...
  7. Fridrich ME, Akimova E, Huf W et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol 2016; 19. pii: pyv126. Go to original source... Go to PubMed...
  8. Stübner S, Grohmann R, Greil W, Zhang X, Müller-Oerlinghausen B, Bleich S et al. Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP multicentre drug safety surveillance project. Int J Neuropsychopharmacol 2018; 21: 814-821. Go to original source... Go to PubMed...
  9. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; Suppl. 334: 1-100. Go to original source... Go to PubMed...
  10. Vinar O. Scale for rating treatment emergent symptoms in psychiatry DVP. Act Nerv Super (Praha) 1971; 13: 238-240. Go to PubMed...
  11. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther 2000; 26: 25-40. Go to original source... Go to PubMed...
  12. Clayton AH, McGarvey EL, Clavet GJ. The changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability and validity. Psychopharmacoll Bull 1997; 33: 731-745.
  13. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Qustionnaire short-form (CSFQ-14). J Sex Marital Ther 2006; 32: 43-52. Go to original source... Go to PubMed...
  14. McIntyre RS, Best MW, Bowie CR et al. The THINC-Integrated Tool (THINC-it) screening assessment for cognitive dysfunction: Validation in patients with major depressive disorder. J Clin Psychiatry 2017; 78: 873-881. Go to original source... Go to PubMed...
  15. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. British Journal of Psychiatry. 1995;167: 99-103. Go to original source... Go to PubMed...
  16. Nakonezny PA, Carmody TJ, Morris DW Kurian, BT Trivedi MH. Psychometric evaluation of the Snaith-Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. Int Clin Psychopharmacol 2010; 25: 328-333. Go to original source... Go to PubMed...
  17. Tondo L, Baldesarini RJ. Antisuicidal effects in mood disorders: Are they unique to lithium? Pharmacopsychiatry 2018; 51: 177-188. Go to original source... Go to PubMed...
  18. Silhan P, Urinovska R, Kacirova I, Hyza M, Grundmann M, Ceskova E. What does antidepressant drug level monitoring reveal about outpatient treatment and patient adherence? Pharmacopsychiatry 2018 doi: 10.1055/s-0044-101838. Go to original source... Go to PubMed...
  19. Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry 2010; 7: 14-18. Go to original source...
  20. Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1289 New Zealanders while taking antidepressants. Psychiatry Res 2014; 30; 216: 67-73. Go to original source... Go to PubMed...
  21. Hughes S, Lacasse J, Fuller RR, Spaulding-Givens J. Adverse effects and treatment satisfaction among online users of four antidepressants. Psychiatry Res 2017; 255: 78-86. Go to original source... Go to PubMed...
  22. Zajecka JM. Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry 2007;68 Suppl 10: 23-27.
  23. Češková E. Některé aspekty účinnosti a snášenlivosti antidepresiv podstatné pro běžnou klinickou praxi. Psychiatr praxi 2016; 17: 48-52. Go to original source...
  24. Češková E, Šedová M, Kellnerová R, Starobová O. Once-a-day trazodone in the treatment of depression in routine clinical practice. Pharmacology 2018; 102: 206-212. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.